Last updated: November 9, 2026
MACI is Vericel’s commercial autologous cell-therapy product for repairing symptomatic full-thickness cartilage defects of the knee. Its market position rests on FDA approval, surgeon adoption, reimbursement, manufacturing capacity, and a specialized two-stage treatment pathway rather than on conventional small-molecule patent protection. MACI is Vericel’s largest revenue product and the main driver of its long-term growth profile.
What is MACI and how does the FDA regulate it?
MACI, or autologous cultured chondrocytes on porcine collagen membrane, is manufactured from a patient’s own cartilage cells. The product is indicated for adults aged 18 to 55 with symptomatic, single or multiple full-thickness cartilage defects of the knee measuring 3 to 10 cm².[1]
| Regulatory attribute |
MACI status |
| Sponsor |
Vericel Corporation |
| FDA application |
Biologics License Application 125684 |
| FDA approval |
December 13, 2016 |
| Product type |
Autologous cultured chondrocyte-cell therapy |
| Delivery system |
Implantable porcine type I/III collagen membrane |
| Indication |
Symptomatic full-thickness cartilage defects of the knee |
| Patient age |
Adults 18 to 55 |
| Treatment model |
Two-stage procedure |
| Manufacturing model |
Patient-specific, centralized manufacturing |
| FDA exclusivity |
12-year reference-product exclusivity under the BPCIA, subject to statutory interpretation and applicable extensions |
| Orange Book status |
Not listed as a conventional small-molecule drug product |
MACI requires an initial arthroscopic biopsy, shipment of the tissue to Vericel, cell expansion and seeding onto the collagen membrane, and a later implantation procedure. The process creates operational barriers that are more important commercially than the price of the implant alone.
How large is the MACI market?
The addressable market is the population of patients with focal cartilage defects who are young or middle-aged, symptomatic, and appropriate for cartilage restoration rather than total knee replacement or routine arthroscopy.
The market is constrained by diagnosis and treatment selection. Many patients with knee pain have osteoarthritis, diffuse cartilage loss, meniscal disease, obesity-related joint stress, or malalignment. MACI is designed for focal defects, which makes the clinically eligible population smaller than the broader knee-pain market.
What drives MACI adoption?
The principal demand drivers are:
- Increasing use of cartilage-restoration procedures among younger active patients.
- Avoidance or postponement of knee arthroplasty.
- Greater surgeon familiarity with matrix-induced autologous chondrocyte implantation.
- Improved reimbursement coverage and coding clarity.
- Vericel’s orthopedic sales force and surgeon-training infrastructure.
- Clinical evidence supporting durability and functional improvement in appropriate patients.
The principal constraints are the two-stage procedure, the need for specialized orthopedic surgeons, patient screening, operating-room scheduling, manufacturing lead times, and payer authorization.
MACI competes with osteochondral autograft transfer, osteochondral allograft transplantation, microfracture, bone marrow stimulation, and other cartilage-repair techniques. These alternatives are not direct generic substitutes because they differ in patient selection, surgical technique, reimbursement, and clinical durability.
What is the financial trajectory of MACI and Vericel?
MACI has been Vericel’s primary growth product since its 2016 approval. Vericel reports revenue by product, with MACI accounting for the majority of company sales and Epicel providing the remainder of the commercial base.[2]
| Period |
Vericel financial direction |
MACI financial direction |
| 2016-2018 |
Commercial launch and infrastructure buildout |
Early adoption from a small base |
| 2019-2020 |
Revenue expanded despite COVID-19 procedure disruption |
Continued procedure-volume growth, with temporary pandemic pressure |
| 2021-2022 |
Recovery in elective orthopedic procedures |
Stronger case volumes and broader surgeon adoption |
| 2023 |
Company revenue reached more than $200 million |
MACI remained the dominant revenue contributor |
| 2024 outlook |
Continued double-digit commercial growth targeted by management |
Growth dependent on procedure volume, capacity, reimbursement, and sales execution |
Vericel’s annual reports show a transition from a development-stage cell-therapy company to a commercial specialty-biologics business. MACI revenue growth has generally been driven by procedure volume rather than by broad population expansion.
What is MACI’s revenue exposure for Vericel?
MACI represents the majority of Vericel’s product revenue. Epicel, an autologous cultured epidermal-cell product for severe burns, provides a second revenue stream but has a smaller and more specialized market.
This concentration creates two opposing effects:
- MACI gives Vericel a clear growth engine with a large orthopedic commercial opportunity.
- The company remains exposed to orthopedic procedure volumes, reimbursement changes, manufacturing interruptions, and surgeon adoption rates.
Vericel does not disclose MACI gross profit in the same detail as total-company results. Profitability depends on manufacturing utilization, batch success, labor, logistics, sales expenses, patient acquisition, and the cost of maintaining specialized facilities.
When does MACI lose regulatory exclusivity?
MACI received FDA approval in December 2016. Under the Biologics Price Competition and Innovation Act, a reference biological product generally receives 12 years of reference-product exclusivity from first licensure. On that basis, the core U.S. reference-product exclusivity period would run into December 2028, before considering any applicable statutory adjustments.[3]
Regulatory exclusivity does not equal patent expiration. A competitor could face:
- FDA reference-product exclusivity;
- patent claims covering manufacturing, cell expansion, scaffolds, or methods of use;
- clinical and technical requirements for a biosimilar or competing cell therapy;
- facility and chain-of-identity requirements;
- physician and payer adoption barriers.
MACI’s regulatory protection is therefore likely to remain commercially meaningful after the earliest patent expiration date, especially because a patient-specific autologous product is difficult to reproduce through a conventional generic pathway.
What patents protect MACI?
MACI does not fit the standard Orange Book patent model used for tablets, capsules, and injectable small molecules. The product is licensed under a BLA, and biological-product patent information is not presented through the same Orange Book framework used for approved small-molecule drugs.
The relevant intellectual-property categories include:
| Protection category |
Commercial relevance |
| Cell-expansion methods |
Protects culture conditions and production workflows |
| Chondrocyte seeding methods |
Protects the process of applying cells to the collagen scaffold |
| Scaffold and membrane technology |
Protects the collagen carrier and cell-support structure |
| Manufacturing controls |
Protects process parameters, testing, and release specifications |
| Patient-specific logistics |
Creates operational know-how around biopsy, transport, production, and implantation |
| Method-of-use claims |
May cover repair of focal cartilage defects using cultured autologous chondrocytes |
| Trade secrets |
Can protect process details that are difficult to identify from the finished product |
A complete MACI patent analysis requires claim-level review of Vericel, former Genzyme, and related assignee portfolios across the United States and other jurisdictions. Public FDA materials do not provide an Orange Book-style definitive list of MACI patents.
The practical patent position is stronger than a single composition-of-matter patent would suggest because a competitor must reproduce the treatment workflow, demonstrate product consistency, establish a compliant manufacturing process, and obtain regulatory approval.
How strong is the MACI patent and regulatory estate?
MACI has a moderate-to-strong commercial protection profile, but its strength comes from several layers rather than a single blocking patent.
Strong protection factors
- FDA approval for a defined cartilage-repair indication.
- Twelve-year reference-product exclusivity under the BPCIA framework.
- Patient-specific manufacturing.
- Specialized cell-processing equipment and quality systems.
- Clinical and physician adoption barriers.
- Proprietary know-how in cell expansion and product release.
- High switching costs for surgeons and treatment centers.
Weaknesses and limitations
- Autologous cell therapy does not necessarily support broad composition-of-matter claims.
- Patent terms may expire at different times.
- Competitors could pursue distinct scaffolds or cell-processing approaches.
- Osteochondral grafts and other procedures do not need to copy MACI.
- A competing allogeneic cartilage product could target the same clinical market through a different regulatory route.
- Regulatory exclusivity eventually expires, even if manufacturing complexity remains.
The most credible long-term threat is not a conventional generic tablet. It is a competing cartilage-restoration platform with a simpler procedure, shorter treatment timeline, lower cost, or improved reimbursement profile.
Are there Paragraph IV challenges to MACI?
A conventional Paragraph IV challenge is unlikely to be the primary pathway for MACI because Paragraph IV litigation applies to patents listed in the FDA Orange Book for abbreviated new drug applications.
MACI is approved under a BLA rather than a standard new drug application. A future competitor would more likely pursue a biosimilar or other biologic regulatory pathway, or seek approval for a distinct cell-therapy product with its own clinical and manufacturing package.
No major publicly reported Paragraph IV litigation involving MACI is identified in the FDA approval framework or Vericel’s principal public disclosures through the available reporting period. The absence of a Paragraph IV dispute does not eliminate competitive risk. It reflects the product’s biologic and cell-therapy classification.
What biosimilar risks exist for MACI?
Biosimilar risk is lower and more complex than for a conventional recombinant protein.
A MACI follow-on product would need to address:
- autologous cell sourcing;
- identity and chain of custody;
- cell expansion;
- cellular phenotype and potency;
- scaffold integration;
- sterility and release testing;
- patient-specific manufacturing;
- surgical implantation;
- clinical comparability.
A biosimilar applicant might attempt to demonstrate similarity to MACI, but the individualized nature of the product makes interchangeability and manufacturing comparability difficult. A competing product could instead pursue a separate BLA for an allogeneic or otherwise modified cartilage-repair therapy.
The most likely competitive sequence is:
- Alternative surgical technologies continue taking share in selected patients.
- Follow-on biologic or cell-therapy developers target differentiated products.
- Direct MACI biosimilar competition remains limited unless manufacturing technology changes materially.
- Price competition increases only after a credible alternative achieves reimbursement and surgeon adoption.
What is the MACI litigation and settlement status?
No major publicly reported U.S. patent litigation or Paragraph IV settlement has materially altered MACI’s commercial exclusivity profile through the available reporting period.
Vericel’s principal business risks have been commercial and operational rather than litigation-driven. These include product manufacturing, regulatory compliance, reimbursement, procedure volumes, facility capacity, and expansion of the orthopedic sales organization.
A settlement-driven generic-entry date is therefore not a current central assumption for MACI forecasting.
What manufacturing barriers protect MACI?
Manufacturing is one of MACI’s most important barriers to entry. Each product is linked to an individual patient, creating a chain-of-identity requirement from biopsy through implantation.
The process requires:
- controlled receipt of patient tissue;
- validated cell expansion;
- seeding onto the collagen membrane;
- testing and release;
- temperature-controlled shipment;
- coordination with the implantation procedure.
Unlike a conventional drug, inventory cannot be produced in advance for broad distribution. Manufacturing capacity must scale with surgical scheduling and patient enrollment. Failures in biopsy quality, cell expansion, sterility, logistics, or implantation timing can affect both revenue and patient outcomes.
Vericel’s investment in manufacturing infrastructure has strategic value because it supports regulatory compliance and makes rapid competitive entry more difficult. Capacity expansion can also improve fixed-cost absorption and gross-margin performance if procedure volumes continue to rise.
How does MACI compare with other cartilage-repair products?
| Treatment |
Product model |
Procedure profile |
Main competitive issue |
| MACI |
Autologous chondrocytes on collagen membrane |
Two-stage |
Manufacturing complexity and reimbursement |
| Microfracture |
Bone-marrow stimulation |
Usually one-stage |
Lower cost but variable durability |
| Osteochondral autograft |
Patient’s own cartilage and bone |
Usually one-stage |
Donor-site limitations and defect size |
| Osteochondral allograft |
Donor tissue |
Usually one-stage |
Tissue availability and logistics |
| Particulated cartilage |
Cartilage fragments or graft material |
Often one-stage |
Variable evidence and product standardization |
| Knee arthroplasty |
Joint replacement |
Major surgery |
Usually aimed at more advanced disease |
MACI’s commercial opportunity is largest where surgeons want a biological repair option for focal defects and where patients are too young or clinically inappropriate for arthroplasty.
What generic launch scenarios exist for MACI?
Scenario 1: No direct follow-on before the late 2020s
This is the most favorable scenario for Vericel. MACI maintains regulatory and operational exclusivity while procedure volumes expand.
Scenario 2: Alternative cell therapy launches after 2028
A competitor could pursue a differentiated BLA rather than a biosimilar pathway. Market entry would depend on clinical evidence, manufacturing scale, reimbursement, and surgeon confidence.
Scenario 3: Surgical substitutes take share
Osteochondral allografts, autografts, microfracture, or new scaffold technologies could reduce MACI utilization without infringing MACI patents or requiring a direct regulatory challenge.
Scenario 4: Reimbursement pressure
Payers could limit coverage, impose prior authorization, or favor lower-cost procedures. This scenario would affect revenue before patent or regulatory exclusivity ends.
Which companies are challenging MACI?
No company has established a direct, FDA-approved U.S. commercial substitute that matches MACI’s product and indication through the available reporting period.
The competitive field includes:
- orthopedic companies selling grafting systems;
- tissue banks supplying osteochondral allografts;
- developers of cartilage scaffolds;
- regenerative-medicine companies developing cell therapies;
- hospitals and surgeons using microfracture or autograft procedures.
Competition is therefore fragmented. MACI’s principal threat is market substitution rather than an immediate generic launch.
What is the geographic coverage of MACI?
MACI’s commercial value is primarily tied to the United States, where Vericel has FDA approval, a direct sales organization, reimbursement infrastructure, and centralized manufacturing.
International expansion would require:
- country-specific regulatory approval;
- local reimbursement;
- manufacturing or import controls;
- patient-tissue logistics;
- surgeon training;
- compliance with cell and tissue regulations.
Because MACI is patient-specific, international expansion is more difficult than exporting a conventional pharmaceutical product. Geographic growth could require regional manufacturing or highly reliable cross-border logistics.
Key Takeaways
- MACI is Vericel’s principal growth product and the largest contributor to company revenue.
- FDA approval occurred in December 2016 for symptomatic full-thickness knee cartilage defects in adults aged 18 to 55.
- The 12-year BPCIA reference-product exclusivity period points to late 2028 as the core U.S. regulatory exclusivity milestone.
- MACI is not a conventional Orange Book product, and Paragraph IV litigation is not the expected primary challenge route.
- Its protection comes from regulatory exclusivity, manufacturing know-how, patient-specific logistics, clinical evidence, and surgeon adoption.
- Direct biosimilar competition is difficult because the product is autologous and individualized.
- The major near-term risks are reimbursement, procedure volume, manufacturing capacity, and alternative cartilage-repair procedures.
- The company’s long-term revenue trajectory depends on expanding MACI utilization while maintaining Epicel as a second commercial base.
FAQs
Is MACI a drug or a medical device?
MACI is an FDA-licensed biological product and cell therapy delivered on a collagen membrane. It is not regulated as a conventional small-molecule drug or standalone orthopedic device.
Does MACI have a patent listed in the Orange Book?
MACI is approved under a BLA and is not treated like a conventional Orange Book small-molecule product. Relevant protection may involve patents, regulatory exclusivity, manufacturing know-how, and method-of-use rights.
Can a generic company copy MACI?
A conventional generic cannot simply copy MACI through an abbreviated new drug application. A competing company would likely need a biologic or cell-therapy regulatory strategy and would face complex patient-specific manufacturing requirements.
What is the biggest commercial threat to MACI?
The largest commercial threat is substitution by other cartilage-repair procedures or a new regenerative product with a simpler one-stage procedure, lower cost, or better payer coverage.
Is MACI revenue recurring?
MACI revenue is procedure-driven rather than subscription-based. Repeat revenue depends on new eligible patients, surgeon utilization, reimbursement, and the expansion of cartilage-restoration procedures.
References
- U.S. Food and Drug Administration. (2016). MACI prescribing information. https://www.accessdata.fda.gov
- Vericel Corporation. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov
- U.S. Food and Drug Administration. (2023). Regulatory considerations for demonstrating biosimilarity to a reference product. https://www.fda.gov
- Vericel Corporation. (2024). Fourth-quarter and full-year financial results and corporate updates. https://investors.vcel.com
- U.S. Congress. (2010). Patient Protection and Affordable Care Act, Title VII: Improving access to innovative medical therapies. Pub. L. No. 111-148.